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Abstract 
Objectives: Most patients with myelodysplastic syndromes present with single or 
multiple lineage cytopenias in peripheral blood despite a hypercellular bone marrow. 
Thrombocytopenia, attributable to ineffective platelet production by dysfunctional 
megakaryocytes, has been estimated to occur in 40-65% of patients. However, there 
are hardly any studies on the clinical relevance of low platelet counts in MDS. 
Methods: We retrospectively analysed data from 2900 patients in the Duesseldorf 
MDS Registry who where diagnosed at our laboratory between 1982 and 2007.  
Results: At the time of diagnosis, 43% of the patients had a platelet count lower than 
100,000/µl. Platelets were lower than 20,000/µl in 7% of the patients, especially in 
those with advanced stages of MDS, who showed a higher frequency of thrombo-
cytopenia and platelet transfusion dependency. On multivariate analysis, platelet 
anisometry, hypocellularity of megakaryopoiesis, maturational defects of megakaryo-
cytes and platelets <20,000/µl were independent variables showing a statistically 
significant correlation (p<0.05) with clinical signs of bleeding. Platelets lower than 
100,000/µl were associated with significantly shortened survival (p<0.00005), due to 
  
an increased risk of progression to AML (30% vs. 21%) (p<0.02) and bleeding (16% 
vs. 8%) (p=0.0005).   
Conclusions: Thrombocytopenia is a strong predictor of short survival, with or 
without haemorrhagic complications. 
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Introduction 
Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired clonal 
stem cell disorders, characterized by ineffective haematopoiesis, morphologic and 
functional abnormalities of haematopoietic cells, and an increased risk of trans-
formation into acute myeloid leukemia (AML). Most patients with MDS present with 
single or multiple lineage cytopenias in peripheral blood despite a hypercellular bone 
marrow. Platelet counts and haemoglobin values at diagnosis appear to be in inverse 
proportion to the length of survival (1, 2). Rough estimates of the frequency of 
thrombocytopenia in MDS range between 40% and 65% (3) but exact data have not 
yet been reported. Isolated thrombocytopenia is the presenting manifestation in 5-
10% of MDS patients, and may be mistaken for ITP (4). Thrombocytopenia in MDS is 
mainly caused by ineffective platelet production due to disturbed proliferation and 
maturation of megakaryocytes or their precursors. Morphological studies showed 
dysplastic features including micromegakaryocytes, large mononuclear forms, 
multiple separated nuclei, dissociation between cytoplasmic and nuclear maturation, 
and megakaryocytic hypogranulation (5). Cytogenetic studies revealed that even in 
case of a normal appearance on light microscopy, the majority of megakaryocytes 
  
are part of the MDS clone (6). Besides thrombocytopenia, platelet dysfunction may 
contribute to haemorrhagic complications in MDS (3). In the present study, we 
evaluated the clinical impact of platelet count at diagnosis, platelet and 
megakaryocyte morphology, signs of bleeding, and platelet transfusion dependency. 
 
 
Design and Methods 
Between 1982 and 2007, 3259 patients with MDS were diagnosed in our 
haematological cytology laboratory and included in the Duesseldorf MDS Registry 
with their informed consent. The median duration of observation was 18 months. The 
diagnostic procedures were the same as reported in our previous studies (7, 8). All 
blood and bone marrow smears were examined by the same two investigators C. A. 
and/or U. G. at our haematologic laboratory. The morphological diagnosis was made 
according to the proposals of the FAB (9) as well as on the basis of the WHO 
classification (10). Patients with CMML I or II and patients with RAEB-T were also 
included in the analysis. A peripheral blood smear was examined to determine the 
differential white blood count, recognize circulating blast cells, and assess platelet 
morphology. In the marrow, a differential count of 500 nucleated cells was performed 
to determine the proportion of medullary blasts. Megakaryopoiesis was analyzed with 
regard to dysmaturity and dysplastic features of megakaryocytes. Dysmegakaryo-
poiesis was diagnosed if at least 10 out of 25 megakaryocytes were micro-
megakaryocytes, mononuclear megakaryocytes, or had multiple widely separated 
nuclei. Dysmaturity included all other features representing disturbed maturation 
without clear dysmegakaryopoietic criteria. In particular, dysmaturity included small 
megakaryocytes but not micromegakaryocytes; hypolobated but not mononuclear 
megakaryocytes, bizarre megakaryocytes but not hyperlobated megakaryocytes. 
  
Cytogenetic analysis by metaphase karyotyping was performed in the Institute of 
Human Genetics, Heinrich-Heine University, Duesseldorf. If possible, patients were 
assessed according to the International Prognostic Scoring System (IPSS) (11) and 
followed for platelet transfusion requirement (due to bleeding or thrombocytopenia 
<10,000/µl), signs of bleeding, and cause of death. Patients were considered platelet 
transfusion dependent if platelets had to be administered at least once per month. 
Petechiae, haematomas and gastrointestinal or intracerebral bleeding were taken as 
evidence of haemorrhagic diathesis. Patients who received induction chemotherapy 
or allogeneic stem cell transplantation were excluded from the survival analysis. 
Clinical and haematological data at the time of diagnosis were compared using the χ-
square and Wilcoxon rank sum test. A two-sided p-value of less than 0.05 was 
considered statistically significant. 
 
 
Results 
Our analysis included 2900 patients whose platelet count at diagnosis was available 
in the MDS Registry. Information on bleeding at diagnosis and platelet transfusions 
during the course of disease was available for 1373 and 1250 patients, respectively. 
Blood and bone marrow smears of 2475 patients were evaluable for platelet and 
megakaryocyte morphology. The IPSS was applicable to 1064 patients. The 
male:female ratio was 53:47. The median age was 71 years (range: 16-96 years). 
Since the majority of patients was older than 65, we did not try to adjust bone marrow 
cellularity for age.  
 
Platelet count 
  
At the time of diagnosis, the median leukocyte count was 4,300/µl, the median 
granulocytes were 2,000/µl, and the median haemoglobin was 9.5 g/dl. Median 
platelet count was 116,000 (range: 1-1,600,000). Platelet counts were >100,000/µl in 
57% of patients, between 100,000/µl and 50,000/µl in 23%, between 50,000/µl and 
20,000/µl in 13%, and below 20,000/µl in 7% of patients. Distribution of patients 
among WHO types of MDS was as follows: 5.5% RA, 8.3% RARS, 11.6% RCMD-
RS, 18.3% RCMD, 1.7% 5q- syndrome, 11.7% RAEB-I, 15.4% RAEB-II, 11% CMML-
I, 3% CMML-II, and 13% RAEB-T. 
Tables 1a and 1b show the mean platelet count and the percentage of patients with 
thrombocytopenia <50,000/µl and <20,000/µl, respectively, according to the FAB and 
WHO classification. In general, patients with advanced stage MDS had lower platelet 
counts than patients with early stage MDS. Although 0% and 1% of patients with 
RARS had platelet counts of <20,000/µl and <50,000/µl, respectively, at the time of 
diagnosis, 4% of RARS patients presented with hemorrhagic diathesis, suggesting 
platelet dysfunction in a proportion of MDS patients. Risk assessment according to 
the International Prognostic Scoring System (IPSS) showed that at the time of 
diagnosis, 20% of patients scored as low-risk, 31% as intermediate-1, 21% as 
intermediate-2, and 28% as high-risk. The median platelet count was 240,000/µl in 
the IPSS low-risk group and clearly decreased in accordance with more unfavourable 
IPSS scores (Table 1c). In the high-risk group, 17% of patients had a platelet count 
lower 20,000/µl. 
 
Bleeding complications 
Signs of bleeding at the time of diagnosis were present in 19% of all patients. The 
frequency of haemorrhagic diathesis at diagnosis is shown in table 1a and 1b 
according to FAB and WHO type of MDS, respectively, and in table 1c according to 
  
IPSS score. Patients with advanced WHO types or unfavourable IPSS scores 
showed more frequent bleeding, lower platelet counts, and higher platelet transfusion 
requirements.  
Platelet transfusion dependency developed during the course of disease in 20% of 
patients. In the majority (63%), a bleeding tendency manifested itself as petechiae. 
Gastrointestinal haemorrhages occurred in 16% and epistaxis or oral mucosal 
bleedings in 13% of patients. Haematuria and haemorrhagic retinopathy occurred as 
initial signs of bleeding in 7% and 1%, respectively.  
As expected, haemorrhagic diathesis already correlated with platelet counts at the 
time of diagnosis. In patients with platelets lower than 20,000/µl or lower than 
50,000/µl, signs of bleeding were significantly more frequent (50.6% and 45.5%, 
respectively; p<0.0005) than in patients showing higher platelet counts. In patients 
with platelets >50,000/µl, we found signs of bleeding in 19% (data not shown). This 
may be attributable to platelet dysfunction.  
Splenomegaly was present at diagnosis in 17.8% of all patients, with an even 
distribution among WHO types and IPSS risk groups. Interestingly, signs of bleeding 
were significantly more frequent at the time of diagnosis in patients with 
splenomegaly (p<0.0001), irrespective of platelet count or features of dysmega-
karyopoiesis (data not shown). The frequency of marrow fibrosis was similar in 
patients with or without splenomegaly (20% vs. 17%). 
 
Signs of dysmegakaryopoiesis 
Anisometry of platelets and “giant platelets” were found in 35% and 17% of the blood 
smears, respectively. In the bone marrow, signs of dysmaturity were found in 41%, 
mononuclear megakaryocytes in 28%, micromegakaryocytes in 22%, and mega-
karyocytes with separated nuclei in 24% of the cases. The marrow was hypocellular 
  
in 13%, normocellular in 34%, and hypercellular in 53% of patients according to bone 
marrow biopsy. Megakaryopoiesis was hypocellular in 24.4%, normocellular in 45%, 
and hypercellular in 21% of cases. Table 2 gives the frequency of dysmegakaryo-
poietic features in MDS subgroups according to WHO classification and IPSS score.  
A significant correlation was found between the presence of platelet anisometry and 
the occurrence of bleeding (62.2% vs. 46.5%; p<0.0005). Hypocellularity of 
megakaryopoiesis, found in 37.9% of patients with haemorrhagic diathesis, and 
maturational defects of megakaryocytes, found in 23%, were also significantly 
correlated with bleeding (p<0.0005, data not shown). On multivariate analysis, 
platelet anisometry, hypoplastic megakaryopoiesis, maturation defects of 
megakaryocytes, and platelet counts <20,000/µl were independent variables 
significantly predicting the risk of bleeding (p<0.05, Table 3). Micromegakaryocytes, 
mononuclear megakaryocytes, and megakaryocytes with separated nuclei were not 
identified as independent risk factors.  
 
Survival 
Patients with platelet counts lower than 20,000/µl at the time of diagnosis had the 
shortest survival (median: 7 months). Chances of survival increased with the number 
of platelets at diagnosis. The longest survival (median: 41 months) was seen in 
patients with a normal platelet count. Patients with a platelet count of <50,000/µl at 
the time of diagnosis had a statistically significantly shorter survival (p<0.00005, 
Figure 1a). On multivariate analysis, platelets <100,000/µl and hemoglobin <10 g/dl 
were associated with significantly shortened survival (p<0.00005), whereas an 
absolute neutrophil count <1,800/µl had no significant influence on survival 
(p=0.599). The risk of progression to AML also increased with lower platelet counts at 
diagnosis. Patients with initial platelet counts <100,000/µl, <50,000/µl, and <20,000/µl 
  
showed a progressively increasing risk of AML transformation. Development of AML 
was significantly more frequent in patients with a platelet count <50,000/µl at the time 
of diagnosis (p=0.00005, Figure 1b).  
 
Causes of death 
The cause of death was known in 1077 patients and was disease-related in 89%. 
Infections and progression to AML were the most frequent causes of death (32% and 
30%, respectively), followed by haemorrhagic complications (14%). Causes of death 
according to IPSS score are shown in table 4. Platelets lower than 100,000/µl were 
associated with significantly shortened survival (p<0.00005), due to an increased risk 
of progression to AML (30% vs. 21%) (p<0.02) and bleeding (16% vs. 8%) 
(p=0.0005). Patients who later died of bleeding complications had a significantly 
lower median platelet count at diagnosis (72,000/µl) than patients who died from 
other causes (median 113,000/µl) (p=0.005).  
Discussion 
In this retrospective study, we tried to determine the magnitude of the problem of 
thrombocytopenic bleeding in patients with MDS. First, we found that 41% of all 
patients showed platelet counts lower than 100,000/µl at the time of diagnosis. This 
is in line with previous estimates ranging between 40% and 65%. Kantarjian et al (3) 
found that 66% of patients with MDS develop thrombocytopenia during the course of 
disease. As expected, our data showed that frequencies of thrombocytopenia and 
platelet transfusion dependency correlated with advanced stages of MDS according 
to WHO and unfavourable risk profile according to IPSS.  
How often do we see clinical manifestations of thrombocytopenia? Signs of 
haemorrhagic diathesis, mostly petechiae, were found in 18% of patients at the time 
of diagnosis. A more severe clinical manifestation, namely gastrointestinal bleeding, 
  
was encountered during the course of disease in 16% of the patients. Twenty percent 
of patients became dependent on platelet transfusions during the course of their 
disease. 
Is haemorrhagic diathesis predictable from morphological features? On multivariate 
analysis, we found that hypocellularity of megakaryopoiesis, microscopically 
discernible defects of megakaryocyte maturation, and platelet anisometry were 
independent prognostic markers significantly associated with bleeding complications, 
whereas other features of dysmegakaryopoiesis, namely mononuclear megakaryo-
cytes, micromegakaryocytes, and megakaryocytes with multiple separated nuclei, 
showed no significant correlation with the frequency of haemorrhagic symptoms. Of 
interest, splenomegaly was observed with a frequency of 17.8% in MDS patients, 
with a consistent distribution among all WHO types and IPSS risk groups. Patients 
with splenomegaly had significantly more frequent signs of bleeding, irrespective of 
platelet count, dysplastic features of megakaryopoiesis, or bone marrow fibrosis. 
Therefore, the pathophysiological explanation of this finding remains elusive, and one 
can only speculate whether splenectomy may be beneficial in selected patients.  
Is thrombocytopenia and haemorrhagic diathesis associated with shortened survival? 
This is clearly the case. Patients with platelet counts lower than 20,000/µl at the time 
of diagnosis had the shortest survival (median: 7 months). This is taken into account 
by the IPSS and also by a new risk score recently proposed by Kantarjian et al (12). 
Although it is tempting to speculate that the shortened survival was attributable to 
fatal haemorrhagic complications, platelet counts were also significantly associated 
with an increased risk of AML transformation. Among the most frequent causes of 
death, haemorrhagic complications (14%) were third, behind infections (32%) and 
leukaemic transformation (30%). In our survival analysis, we excluded established 
variables like age, cytogenetics, medullary blast count and performance status since 
  
they are powerful independent variables for disease progression and survival but not 
for bleeding.  
Our finding that the frequency of fatal bleeding was evenly distributed among all 
IPSS risk groups, even though patients with higher IPSS scores presented more 
often with thrombocytopenic bleeding at diagnosis, may be attributable to widespread 
platelet dysfunction in patients with MDS. 
The prognostic value of platelet mass has not yet been clearly defined. Bowles et al 
suggested that a low platelet mass is associated with shorter survival (13). As 
previously reported, platelet volume does not seem to influence the risk of bleeding at 
the time of diagnosis or the risk of fatal haemorrhagic complications (14). 
All in all, thrombocytopenia is a significant clinical problem in patients with MDS, 
partly due to haemorrhagic complications and partly owing to the fact that thrombo-
cytopenia reflects an unfavourable biology of the underlying bone marrow disease, 
thereby predicting additional clinical complications not directly related to the risk of 
bleeding. In order to determine more precisely the clinical significance of 
dysmegakaryopoiesis and thrombocytopenia in MDS, prospective studies are 
required, with meticulous documentation of hemorrhagic features and platelet counts, 
as well as tests of platelet function. 
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Table 1 
1a. Platelet count and frequency of bleeding according to FAB type at diagnosis, 
n=1373 
 
FAB n (%) Platelets     
median      
x 109/l 
(range) 
< 20,000/µl < 50,000/µl Bleeding at 
diagnosis 
Platelet 
transfusion 
in course 
of disease* 
Bleeding 
as cause 
of death 
RA 347 (25,3%) 120 (5-975) 6% 16% 19% 22% 10% 
RARS 278 (20,2%) 225 (8-999) 2% 6% 8% 4% 6% 
RAEB  324 (23,6%) 90 (1-809) 11% 25% 21% 29% 14% 
RAEB-T 229 (16,7%) 77 (3-777) 14% 33% 27% 35% 10% 
CMML 195 (14,2%) 101 (1-744) 6% 16% 22% 12% 12% 
 
* n=1250, only patients with platelet transfusion dependency included 
 
1b. Platelet count and frequency of bleeding according to WHO type at diagnosis, 
n=998 
WHO n (%) Platelets      
median         
x 109/l    
(range) 
< 20,000/µl < 50,000/µl Bleeding 
at 
diagnosis 
Platelet 
transfusion 
in course 
of disease 
Bleeding 
as cause 
of death 
All types 998 (100%) 116 (1-975) 7% 19% 18% 20% 24% 
RA 76 (5,5%) 129 (8-975) 5% 19% 15% 20% 11% 
RCMD 251 (18,0%) 118 (5-823) 8% 15% 22% 24% 4% 
RARS 114 (8,3%) 300 (43-456) 0% 1% 4% 2% 2% 
RCMD-RS 160 (11,6%) 197 (7-450) 6% 9% 13% 9% 8% 
del(5q) 24 (1,7%) 283 (28-676) 0% 5% 0% 5% 5% 
RAEB I 161 (11,7%) 92 (1-778) 10% 21% 23% 27% 12% 
RAEB II 212 (15,4%) 80 (3-809) 12% 29% 20% 35% 15% 
 
 
1c. Platelet count and frequency of bleeding according to IPSS at diagnosis, n=529 
IPSS % Platelets 
median x 109/l     
(range) 
< 20,000/µl < 50,000/µl Bleeding at 
diagnosis 
Platelet 
transfusion 
in course 
of disease 
Bleeding 
as cause 
of death 
Low 20% 240 (10-1500) 2% 7% 5% 12% 14% 
Int 1 31% 100 (2-999) 8% 21% 26% 29% 14% 
Int 2 21% 77 (2-701) 8% 28% 27% 35% 12% 
High 28% 60 (3-809) 17% 40% 43% 32% 13% 
 
  
Table 2  
Features of dysmegakaryopoiesis according to MDS types 
2a. WHO classification 
 
WHO Hypocellularity 
of mega-
karyocytes 
Giant 
platelets 
Platelet 
anisometry 
All Types 24.4 % 17.0 % 35.0 % 
RA 26.5 % 6.1 % 19.2 % 
RCMD 19.9 % 10.9 % 24.0 % 
RARS 7.2 % 7.5 % 29.1 % 
RCMD-RS 11.4 % 16.3 % 35.4 % 
5q- 
syndrome 
4.5 % 24.4 % 51.2 % 
RAEB-I 32.1 % 17.3 % 33.9 % 
RAEB-II 35.9 % 20.6 % 41.8 % 
CMML-I 23.2 % 29.1 % 43.8 % 
CMML-II 33.3 % 25.5 % 52.9 % 
 
 
2b. IPSS score; n=957 
IPSS Hypocellularity 
of 
megakaryocytes 
Giant 
platelets 
Platelet 
anisometry 
low 7% 15% 16% 
Int-1 28% 17% 22% 
Int-2 23% 30% 23% 
high 42% 39% 39% 
 
 
Table 3 
Multivariate analysis for the risk of hemorrhagic diathesis in patients with MDS 
 
Parameter χ² Significance 
Platelet anisometry 9,395 0.002 
Hypocellularity of 
megakaryocytes 
5,136 0.023 
Impaired maturation 
of megakaryocytes 
8,828 0.003 
Platelet count < 
20,000/µl 
32,735 0.0005 
  
 
Table 4 
Causes of death according to IPSS risk category; n=427 
initial IPSS  Infection Bleeding Heart 
failure 
AML Other 
disease 
related 
Not 
disease 
related 
low 37.2 % 14.0 % 9.3 % 18.6 % 9.3 % 11.6 % 
Int-1 40.5 % 14.0 % 4.1 % 28.1 % 4.1 % 9.1 % 
Int-2 33.0 % 12.2 % 2.2 % 46.2 % 3.3 % 3.3 % 
high 27.3 % 13.4 % n.a. 52.3 % 4.7 % 2.3 % 
Total 33.3 % 13.3 % 2.6 % 40.7 % 4.7 % 5.4 % 
 
 
Figure 1a 
Cumulative survival of MDS patients according to platelet count 
months
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Figure 1b 
Cumulative risk of AML evolution according to platelet count 
months
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